Antibody-Biopolymer Conjugates in Oncology: A Review.
Vivek P ChavdaPankti C BalarDivya TeliMajid HassanzadeganroudsariJoanna BojarskaVasso ApostolopoulosPublished in: Molecules (Basel, Switzerland) (2023)
Cancer is one of the most prevalent diseases and affects a large proportion of the population worldwide. Conventional treatments in the management include chemotherapy, radiotherapy, and surgery. Although being well-accepted, they have many lacunas in the form of severe side effect resulting from lack of targeted delivery. Antibody biopolymer conjugates are a novel method which is an add-on to older methods of immunization. It is used in various diseases and disorders. It ensures the targeted delivery of molecules to increase its efficacy and reduce unwanted effects of the molecule/drug to normal cells. It shows miraculous results in the treatment and management of several cancers even in advanced stages. Herein, we present the chemistry between biopolymer and antibody, their effects on cancer as well as the basic differences between antibody-drug conjugates and antibody-biopolymer conjugates.
Keyphrases
- papillary thyroid
- cancer therapy
- locally advanced
- induced apoptosis
- squamous cell
- early stage
- minimally invasive
- cell cycle arrest
- radiation therapy
- physical activity
- drug delivery
- atrial fibrillation
- middle aged
- cell death
- palliative care
- childhood cancer
- endoplasmic reticulum stress
- coronary artery disease
- signaling pathway
- coronary artery bypass